Navigation Links
Piramal imaging to present data at Society for Nuclear Medicine Annual Meeting
Date:6/8/2012

Miami Beach, Fla., June 8, 2012: Piramal Imaging SA, a subsidiary of Piramal Healthcare Limited [NSE: PIRHEALTH, BSE: 500302], will present data on several compounds from its molecular imaging portfolio at the Society of Nuclear Medicine's 59th annual meeting in Miami Beach, Fla., from June 9 - 13. Data from five florbetaben studies will be featured, including results from a pivotal Phase III trial which will provide the basis for regulatory submission later this year.

Earlier this spring, Piramal Imaging was formed through the acquisition of worldwide rights to the molecular imaging research and development portfolio of Bayer Pharma AG. Florbetaben, a late-stage amyloid imaging agent being studied as a potential tool to aid in the diagnosis and assessment of Alzheimer's disease, is the lead compound in the portfolio.

Historically, the only way to definitively diagnose Alzheimer's disease has been after death at autopsy through analysis and identification of beta-amyloid in brain tissue. The global Phase III trial employed a unique and rigorous study design comparing in vivo brain positron emission tomography (PET) imaging with florbetaben to post-mortem analysis of the brain tissue. Another study compared florbetaben scans of people with mild cognitive impairment (MCI) over time to assess their risk of developing Alzheimer's disease.

"What better way to introduce Piramal Imaging to the nuclear medicine community," says Dr. Ludger M. Dinkelborg, CEO Piramal Imaging. "We believe we have the richest molecular imaging portfolio in the industry today, and the range of research we are presenting here reflects the depth, diversity and clinical relevance of our pipeline." Before co-founding Piramal Imaging, Dr. Dinkelborg served as Head of Diagnostic Imaging Research and Head of Molecular Imaging at Bayer Healthcare.

Piramal Imaging is developing an innovative and proprietary tracer portfolio to address major clinical needs in Alzheimer's disease, prostate cancer, lung cancer, liver cancer, and cardiovascular disease.

"Our goal is to be a leader in molecular imaging through increased diagnostic accuracy of serious medical conditions to improve patient care," says Dr. Swati A. Piramal, Director, Piramal Healthcare Limited. "On a parallel track with our aggressive clinical development program, we are taking the necessary steps toward bringing our tracers to market through the formation of strategic partnerships." Dr. Piramal was recently elected to the Harvard Board of Overseers and also serves on the Dean's Advisory Board of both the Harvard School of Public Health and Harvard Business School.

At this meeting, research on several of the company's pipeline compounds will be featured, including:

NOTE TO EDITORS: All data is embargoed until the date/time of presentation.

Florbetaben

Multicentre phase 3 trial on florbetaben for β-amyloid brain PET in Alzheimer disease [Abstract #41]
Oral Presentation: Neuroscience Miscellaneous & New Approaches
Sunday, June 10, 1:57 PM - 2:09 PM, Room B217/218
Presenter: Osama Sabri, University of Leipzig, Leipzig, Germany

Longitudinal assessment of cerebral amyloid-β deposition in APP-Swe mice with [18F]florbetaben PET [Abstract #92]
Oral Presentation: Brain Imaging Council Young Investigator Award Symposium
Sunday, June 10, 5:03 PM - 5:15 PM, Room B217/218
Presenter: Axel Rominger, University of Munich, Munich, Germany

Partial volume effect correction of florbetaben β-amyloid (Aβ) PET data improves discrimination between Alzheimer's disease (AD) patients and healthy volunteers (HVs) [Abstract #146]
Oral Presentation: Quantifying Brain Amyloid Signal - Methods & Challenges
Monday, June 11, 10:24 AM - 10:36 AM, Room B217/218
Presenter: Henryk Barthel, University of Leipzig, Leipzig, Germany

A two-year longitudinal assessment of Aβ deposition in MCI with 18F-Florbetaben [Abstract #148]
Oral Presentation: Quantifying Brain Amyloid Signal - Methods & Challenges
Monday, June 11, 10:48 AM - 11:00 AM, Room B217/218
Presenter: Kevin Ong, Centre for PET, Austin Health, Melbourne, VIC, Australia

In vivo PET imaging of β-amyloid plaques in an APP/PS1 mouse model of Alzheimer's disease: Comparison of [18F]FIBT and [18F]Florbetaben with [11C]PiB [Abstract #1630]
Poster Presentation: Probes for Neuroimaging
Sunday, June 10, 7:04 PM - 7:06 PM, Exhibit Hall A-B
Presenter: Behrooz Hooshyar Yousefi, Technische Universitt Mnchen, Munich, Germany

FSPG

Correlation of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate ([18F]FSPG) uptake by positron emission tomography (PET) with immunohistochemical expression of system xC- and CD44 in cancer patients [Abstract #219]
Oral Presentation: Basic Science (Oncology); Tumor Characterization & Microenvironment
Monday, June 11, 5:18 PM - 5:30 PM, Room B118/119
Presenter: Dae Hyuk Moon, University of Ulsan College of Medicine, Seoul, Republic of Korea

Evaluation of the 18F L-glutamate derivative 18F-FSPG (BAY 94-9392) in lymphoma and colon cancer patients [Abstract #1126]
Poster Presentation: Meet the Author Poster Session; Basic Science (Oncology)
Monday, June 11, 2:30 PM - 4:00 PM, Exhibit Hall A-B
Presenter: Meena Kumar, Stanford University Medical Center, Palo Alto, California, USA

Evaluation of the 18F-labeled L-glutamate derivative 18F-FSPG (BAY 94-9392) in brain and head and neck cancer patients [Abstract #274]
Oral Presentation: Basic Science (Oncology); Novel Imaging Agents - Clinical
Tuesday, June 12, 8:36 AM - 8:48 AM, Room B118/119
Presenter: Meena Kumar, Stanford University Medical Center, Palo Alto, California, USA

Characterization of physiological 18F-FSPG uptake in healthy volunteers: Kinetics and biodistribution [Abstract #555]
Oral Presentation: Technological Advances, Methodology, Quantification
Wednesday, June 13, 10:33 AM - 10:45 AM, Room B118/119
Presenter: Camila Mosci, Stanford University, Palo Alto, California, USA

Ga68-Bombesin
Preclinical validation of the Ga-68-Bombesin Antagonist BAY 86-7548 for a Phase I Study in Prostate Cancer Patients [Abstract #177]
Oral Presentation: Prostate
Monday, June 11, 12:30 PM - 12:42 PM, Room B214
Presenter: Sandra Borkowski, Global Drug Discovery, Bayer Healthcare, Berlin, Germany

Radiosynthesis and pre-clinical evaluation of Al18F labeled bombesin antagonist: Promising tracer for prostate cancer imaging [Abstract #1732]
Poster Presentation: Special Meet the Author Poster Session; Probes for Oncology
Sunday, June 10, 6:30 PM - 8:00 PM, Exhibit Hall A-B
Presenter: Svetlana Selivanova, Center for Radiopharmaceutical Sciences, ETH Zurich, Zurich, Switzerland

DFMT

Clinical investigation of dynamic PET/CT imaging using O-([18F]fluoromethyl)-D-tyrosine (D-18F-FMT, BAY 86-9596) in oncological patients [Abstract #1676]
Poster Presentation: Special Meet the Author Poster Session; Probes for Oncology
Sunday, June 10, 6:30 PM - 8:00 PM, Exhibit Hall A-B
Presenter: Irene Burger, University Hospital, Zurich, Switzerland

Comparison of PET/CT images with a novel tracer O-([18F]fluoromethyl)-D-tyrosine (D-18F-FMT, BAY 86-9596) with LAT1 immunohistochemical staining in patients with non-small cell lung cancer or head and neck squamous cell carcinoma [Abstract #1677]
Poster Presentation: Special Meet the Author Poster Session; Probes for Oncology
Sunday, June 10, 6:30 PM - 8:00 PM, Exhibit Hall A-B
Presenter: Irene Burger, University Hospital, Zurich, Switzerland


'/>"/>
Contact: Julie Armour
julie.armour@ketchum.com
908-656-5887
Ketchum New York
Source:Eurekalert

Related medicine news :

1. Fox Chase researchers find no disparities in imaging before breast cancer surgery
2. Study examines necessity of additional imaging in PET/CT oncologic reports
3. Low-dose whole-body CT finds disease missed on standard imaging for patients with multiple myeloma
4. Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose
5. MR enterography is as good or better than standard imaging exams for pediatric Crohns patients
6. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
7. Lung changes are present in nearly half of ACPA positive RA patients at disease onset
8. University Hospitals Case Medical Center experts present at ASCO Annual Meeting
9. Patient mental health overlooked by physician when a family member is present
10. SLEEP 2012 presents latest in sleep medicine and research June 11-13 in Boston
11. Mayo Clinic urologists present findings at American Urological Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... 2016 , ... After a year and a half of planning the Multiple Pathways of ... Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the Mystic ... came together to explore the many pathways individuals use to get into and sustain their ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue ... Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields ... Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health ...
(Date:5/27/2016)... ... , ... This campaign aims to provide a path to improved education and ... and change. , As nearly 795,000 Americans suffering from a new or recurrent stoke ... with an estimated 129,000 of these people dying from stroke, it’s become our nation’s ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the ... for an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center ... Market Committee (FOMC) dot charts are of interest to the press for their noise ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... PUNE, India , May 27, 2016 ... in the instances of hypertension is driving ambulatory blood ... muscles lose their elasticity and their ability to respond ... blood pressure. This condition can lead to various cardiovascular ... and peripheral vascular disease. These diseases are growing in ...
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology: